Skip to main content

Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas.

Publication ,  Conference
Vredenburgh, JJ; Desjardins, A; Herndon, JE; Quinn, J; Rich, J; Sathornsumetee, S; Friedman, HS; Reardon, D; Gururangan, S; Friedman, A
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 20, 2006

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

June 20, 2006

Volume

24

Issue

18

Start / End Page

59S / 59S

Location

Atlanta, GA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

42nd Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Quinn, J., Rich, J., Sathornsumetee, S., … Friedman, A. (2006). Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 24, pp. 59S-59S). Atlanta, GA: AMER SOC CLINICAL ONCOLOGY.
Vredenburgh, J. J., A. Desjardins, J. E. Herndon, J. Quinn, J. Rich, S. Sathornsumetee, H. S. Friedman, D. Reardon, S. Gururangan, and A. Friedman. “Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas.” In JOURNAL OF CLINICAL ONCOLOGY, 24:59S-59S. AMER SOC CLINICAL ONCOLOGY, 2006.
Vredenburgh JJ, Desjardins A, Herndon JE, Quinn J, Rich J, Sathornsumetee S, et al. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 59S-59S.
Vredenburgh, J. J., et al. “Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas.JOURNAL OF CLINICAL ONCOLOGY, vol. 24, no. 18, AMER SOC CLINICAL ONCOLOGY, 2006, pp. 59S-59S.
Vredenburgh JJ, Desjardins A, Herndon JE, Quinn J, Rich J, Sathornsumetee S, Friedman HS, Reardon D, Gururangan S, Friedman A. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 59S-59S.

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

June 20, 2006

Volume

24

Issue

18

Start / End Page

59S / 59S

Location

Atlanta, GA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

42nd Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences